S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin’s Lymphoma

DISEASE CHARACTERISTICS:

Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following subtypes:

Diffuse large B-cell
Mantle cell
High-grade B-cell, Burkitt's, or Burkitt-like
Anaplastic large cell (B-cell phenotype only)

Stage I, IE, or non-bulky* stage II or IIE disease by Ann Arbor classification

Patients who have bulky stage II or IIE disease are ineligible even if, after resection, the measurements are less than 10.0 cm NOTE: *Non-bulky disease defined as any tumor measuring less than 10.0 cm or occupying less than 1/3 of the chest diameter
CD20-expressing disease by flow cytometry or immunoperoxidase staining

Aggressive lymphomas must have at least 1 of the following adverse prognostic factors:

Non-bulky stage II or IIE disease
At least 60 years of age
Zubrod performance status of 2
Lactic dehydrogenase greater than upper limit of normal
All disease must be encompassable in a single radiation port (including any site of resected disease) NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age

Over 18

Performance status

Zubrod 0-2

Life expectancy

Not specified

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Not specified

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
No medical contraindication to study chemotherapy, rituximab, or ibritumomab tiuxetan
No known AIDS syndrome or HIV-associated complex

PRIOR CONCURRENT THERAPY:

Biologic therapy

No prior monoclonal antibody therapy

Chemotherapy

No prior chemotherapy for lymphoma

Endocrine therapy

Not specified

Radiotherapy

See Disease Characteristics
No prior radiotherapy for lymphoma
No concurrent intensity-modulated radiotherapy
Planned involved-field radiotherapy must not encompass more than 25% of active bone marrow space

Surgery

See Disease Characteristics

Other

Concurrent participation in SWOG-8947 or SWOG-8819 allowed